Fanhua BluePlus establishes strategic alliances with Shanghai Biotecan Pharmaceuticals

GUANGZHOU, China, Sept. 06, 2024 (GLOBE NEWSWIRE) — Fanhua Inc. (Nasdaq: FANH) (the “Company” or “FANHUA”), a leading independent provider of technology-driven financial services in China, today announced that, through its wholly-owned subsidiary Fanhua BluePlus Health Management Co., Ltd. (“Fanhua BluePlus”), it has recently signed a strategic cooperation agreement with Shanghai Biotecan Pharmaceuticals Co. Ltd. (“Biotecan”).

Under the strategic cooperation agreement, Fanhua BluePlus and Biotecan will leverage their respective resources and service strengths to collaborate in cutting-edge medical testing, health management, cell therapy and other high-end modern medical and health management services.

Commenting on the deal, Fanhua BluePlus CEO Mr. Qiao Yu said, “We are excited about our strategic cooperation with Biotecan, a pioneering company in clinical molecular diagnostics and biomedicine in China. This fully demonstrates our commitment to meeting customers’ needs for a high-quality life. We look forward to working with Biotecan to safeguard the health and wellness of our customers. As a one-stop health and wellness service platform provider, we will continue to seek partnerships with leading biopharmaceutical companies to connect health and wellness service providers with biopharmaceutical companies and provide more customers with comprehensive healthcare solutions.”

About Fanhua BluePlus

Fanhua BluePlus Health Management Co., Ltd., a comprehensive wellness service platform under the control of Fanhua Inc., was established in 2010 and has been deeply involved in the industry for 13 years. With partnerships with over 110 top-tier domestic medical, wellness and financial institutions, Fanhua BluePlus provides health and wellness services to over 50,000 customers annually. The platform offers a comprehensive product matrix that fully addresses customers’ needs in “prevention, medical care, nursing, health maintenance and elderly care.”

About Biotecan

Established in 2008, Shanghai Biotecan Pharmaceuticals Co. Ltd. has more than 20 subsidiaries and is a pioneer in clinical molecular diagnostics in China. It has partnered with more than 120 Grade III Class A hospitals nationwide to establish molecular medical centers, providing precision medical molecular diagnostics and clinical research services to more than 1,000 hospitals. The in-hospital laboratory network established by Biotecan offers more than 2,000 precision medical services covering oncology, chronic diseases, maternal and child health, infectious diseases, gut microbiome diseases, and general health screening. More than 200 million visitors to Biotecan receive outpatient and emergency treatment per year.

The story continues

About Fanhua

Founded in Guangzhou in 1998 and listed on NASDAQ in 2007 (Nasdaq: FANH), Fanhua is a leading independent financial services provider in China with strong technological capabilities and a commitment to empowering financial advisors and fostering sustained value creation for clients.

Our mission revolves around creating an inclusive and collaborative platform for independent financial advisors, as well as diverse financial and insurance sales organizations, enabling our partners to optimize their practices by offering end-to-end business solutions spanning compliance, technology, products, services, operations, capital flow and professional training.

Leveraging advanced technology, artificial intelligence and data-driven insights, Fanhua is at the forefront of revolutionizing financial services delivery, accelerating digital transformation and driving industry growth.

With a comprehensive approach to financial services, we connect millions of Chinese families with various financial institutions and service providers, offering a wide range of opportunities and customized solutions for insurance protection, retirement planning, health management, asset management and family governance services, covering the full lifecycle of our clients’ needs.

Forward-looking statements

This press release contains forward-looking statements. These statements, including statements relating to the Company’s future financial and operating results, are made pursuant to the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by terms such as “will,” “expects,” “believes,” “anticipates,” “intends,” “estimates” and similar statements. Among other things, management’s quotes contain forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about Fanhua and the industry. Potential risks and uncertainties include, but are not limited to, those relating to its ability to attract and retain productive agents, especially entrepreneurial agents, its ability to maintain existing and develop new business relationships with insurance companies, its ability to execute its growth strategy, its ability to adapt to the changing regulatory environment in the Chinese insurance industry, its ability to compete effectively against its competitors, quarterly variations in its operating results caused by factors beyond its control and macroeconomic conditions in China and their potential impact on sales of insurance products. Unless otherwise indicated, all information provided in this press release speaks as of the date hereof, and Fanhua undertakes no obligation to update any forward-looking statements to reflect subsequent events or circumstances, or changes in its expectations, except as required by law. Although Fanhua believes that the expectations expressed in these forward-looking statements are reasonable, it can give no assurance that its expectations will prove to be correct, and investors are cautioned that actual results may differ materially from anticipated results. More information about the risks and uncertainties facing Fanhua is included in Fanhua’s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F.

For more information, please contact:

Fanhua Inc. Company

Investor Relations

Phone: +86 (20) 8388-3191

Email: [email protected]

Fountain:Fanhua Inc.